Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
0 hedge funds and large institutions have $0 invested in Pardes Biosciences, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $66.7K → $0 (-$66.7K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$66.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Barclays
London,
United Kingdom
| – | -$66.7K | -31,037 | Closed |
|
PRDS Hedge Fund Activity: Q4 2023 in Review
0 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q4 2023, worth a combined $0 — down 100% from $66.7K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PRDS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Barclays, exiting entirely with an estimated $66.7K sold.
- 0 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q4 2023, down from 1 in Q3 2023.
- Funds reported $0 of Pardes Biosciences, Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q4 2023 was Barclays, an estimated $66.7K sold.
Based on aggregated 13F filings for Q4 2023.